Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) news covers a commercial-stage pharmaceuticals company focused on plant-based prescription medicines for gastrointestinal distress in humans and animals. The company’s updates frequently highlight progress across its crofelemer programs, regulatory interactions, and partnerships.
Investors following JAGX news can expect coverage of developments related to Mytesi, Napo Pharmaceuticals’ FDA-approved crofelemer product for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, as well as Jaguar’s broader intestinal failure program targeting rare disorders such as short bowel syndrome with intestinal failure (SBS-IF) and microvillus inclusion disease (MVID). News items often describe clinical trial milestones, proof-of-concept data on reductions in parenteral support, and discussions with regulators about potential expedited approval pathways for ultrarare pediatric indications.
On the animal health side, Jaguar news includes information about Canalevia-CA1, the company’s conditionally approved crofelemer-based prescription drug for chemotherapy-induced diarrhea in dogs, along with regulatory grants, conditional approval renewals, and studies designed to support full approval. Updates may also address efforts to obtain guidance from the European Medicines Agency for Canalevia in general diarrhea in dogs.
Corporate and capital markets announcements are another key component of JAGX news. These can include securities purchase agreements, royalty interest amendments, PIPE financings, preferred stock exchanges, and at-the-market offering amendments, as disclosed in Form 8-K filings. Conference presentations, investor summit appearances, and summaries of stockholder meeting results also appear in the company’s news flow.
For investors and observers, the Jaguar Health news page provides a centralized view of clinical, regulatory, commercial, and financing developments that shape the company’s strategy in plant-based gastrointestinal therapeutics for both human and veterinary medicine.
Jaguar Health reported third quarter 2020 financial results, showing significant growth in Mytesi product revenue totaling approximately $2.8 million, a 280% increase from $1.0 million in the same quarter of 2019. Gross sales reached approximately $6.3 million, up 332% year-over-year. Despite increased sales, the company recorded a net loss of $7.9 million, compared to $7.6 million in Q3 2019. Operating expenses rose to $8.1 million, influenced by higher general and administrative costs, including a $2.5 million trial delay fee.
Jaguar Health, Inc. (NASDAQ:JAGX) is set to file its Q3 2020 10-Q report on November 16, 2020. Management will host a conference call at 8:30 a.m. ET to discuss the financial results and provide business updates. Investors can join via dial-in numbers, with a replay option also available. The company is focused on developing plant-based pharmaceuticals to address GI distress, particularly chronic diarrhea. Notably, its product Mytesi® is FDA-approved for treating diarrhea in adults with HIV/AIDS.
Jaguar Health, Inc. (NASDAQ:JAGX) announced that it received an extension from the Nasdaq Hearings Panel until December 23, 2020, to comply with the minimum bid price requirement for continued listing. The company must maintain a bid price of at least $1.00 per share for ten consecutive business days. Jaguar's recent efforts include expanded access programs for Mytesi and a $6 million royalty-based capital infusion. Additionally, Napo Pharmaceuticals initiated a pivotal Phase 3 trial for Mytesi in adult cancer patients experiencing diarrhea.
Jaguar Health (NASDAQ:JAGX) is hosting its inaugural "Diarrhea Dialogues" virtual event on October 20, 2020, from 3:00 PM to 4:30 PM ET, focused on supportive care for cancer patients experiencing diarrhea from cancer therapies. Key experts, including Jaguar's leadership and oncologists, will discuss the impact of diarrhea on cancer treatment and the importance of patient-physician dialogue. Jaguar's subsidiary, Napo Pharmaceuticals, has initiated a pivotal Phase 3 trial for crofelemer (Mytesi) in preventing cancer therapy-related diarrhea, currently approved for HIV/AIDS-related diarrhea relief.
Jaguar Health, Inc. (NASDAQ:JAGX) granted nonstatutory stock options for 45,000 shares to a new employee effective October 13, 2020. The options, at an exercise price of $0.315 per share, are part of the Company's Inducement Award Plan and aim to incentivize new hires. The options vest 25% after nine months and monthly thereafter over the next 27 months, contingent on continued employment. Jaguar Health specializes in plant-based gastrointestinal products, with its MYTESI product approved by the U.S. FDA for treating noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
Napo Pharmaceuticals, a subsidiary of Jaguar Health (NASDAQ:JAGX), unveiled the iAssist platform as part of its NapoCares patient support program. This web-based system automates the prescription process for Mytesi (crofelemer), an FDA-approved, plant-based treatment for diarrhea in HIV/AIDS patients. The platform enhances patient access by simplifying e-prescribing, prior authorizations, and eligibility checks, thereby promoting quicker treatment initiation. AssistRx developed iAssist, which also aids in tracking patient status and managing communications among healthcare providers, patients, and payers.
Jaguar Health has appointed Melissa Yeager, J.D. as Senior Vice President of Regulatory Affairs & Quality Assurance. With extensive experience in the pharmaceutical industry, Yeager's leadership is expected to enhance the regulatory and quality functions at Jaguar and its subsidiary, Napo Pharmaceuticals. This move supports the ongoing commercialization of Mytesi and the pivotal Phase 3 clinical trial for diarrhea prophylaxis in adult cancer patients. Mytesi, a plant-based, FDA-approved antidiarrheal, assists patients with HIV/AIDS on antiretroviral therapy.
Jaguar Health, Inc. (NASDAQ:JAGX) has successfully closed the first $6 million tranche of a non-dilutive royalty financing transaction, potentially totaling $17 million, to support ongoing clinical trials for Mytesi (crofelemer). This financing will aid in developing treatments for cancer therapy-related diarrhea. Additionally, Jaguar has amended its agreement with Oasis Capital, allowing for $2,117,875.20 in accounts receivable purchases. The company aims to achieve financial sustainability in 2021 and has seen a 378% increase in Mytesi's Q2 2020 sales compared to Q1.
Jaguar Health, through its subsidiary Napo Pharmaceuticals, has launched a pivotal Phase 3 trial for crofelemer (Mytesi) aimed at preventing diarrhea in adult cancer patients undergoing targeted therapy. This 24-week, randomized, placebo-controlled study aims to address a significant unmet need as diarrhea affects over 650,000 chemotherapy patients in the U.S. annually. The trial is supported by an increased non-dilutive financing deal, now totaling $17 million, anticipated to expedite patient enrollment and site activation. Mytesi is FDA-approved for HIV/AIDS-related diarrhea, showcasing its therapeutic potential.
Jaguar Health (NASDAQ:JAGX) announced that it has met the financial condition for an initial $5 million tranche of a potential $16 million non-dilutive royalty financing transaction. This financing is designed to support its development pipeline, particularly funding a pivotal clinical trial for Mytesi (crofelemer) aimed at treating cancer therapy-related diarrhea. The company has initiated an at-the-market program with Ladenburg Thalmann for future financing needs and anticipates the trial to start in Q4 2020.
FAQ
What is the current stock price of Jaguar Health (JAGX)?
What is the market cap of Jaguar Health (JAGX)?
